Tucatinib — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

6 Recruiting

5 Completed trials

8 Sponsors

19 Countries

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II/III: 1 Phase II: 6 Phase I/II: 4

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

HER2 positive breast cancer 5 Breast cancer metastatic 2 Breast cancer 1 Colon cancer stage III 1 Oesophageal adenocarcinoma 1 Colon cancer stage II 1 Cholangiocarcinoma 1 Gastric cancer 1

Sponsors using this IMP

Seagen Inc. 5 Institut Curie 2 Unicancer 2 F. Hoffmann-La Roche AG 1 Fundacion Grupo Espanol De Investigacion En Cancer De Mama 1 Gruppo Oncologico Del Nord Ovest 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Medica Scientia Innovation Research S.L. 1

All trials

14 total

Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending

2024-519624-24-00 Phase II 1 country Institut Curie
PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR… Pending

2025-524613-89-00 Phase I/II 1 country Medica Scientia Innovation Research S.L.
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Phase II/III 11 countries F. Hoffmann-La Roche AG
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 Phase I/II 4 countries Seagen Inc.
Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting

2022-502351-60-00 Phase II 1 country Unicancer
Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC) Recruiting

2022-500743-20-00 Phase II 1 country Institut Curie
Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 study Recruiting

2024-518192-61-00 Phase I/II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 Phase III 14 countries Seagen Inc.
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Phase III 12 countries Seagen Inc.
Multi-drug treatment for breast cancer patients with brain metastases Ended

2024-510703-11-00 Phase II 1 country Unicancer
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended

2024-514733-38-00 Phase III 8 countries Seagen Inc.
Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted

2024-515152-20-00 Phase II 1 country Gruppo Oncologico Del Nord Ovest
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Phase I/II 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
Tucatinib and trastuzumab in solid tumors with HER2 alterations Ended

2024-511481-37-00 Phase II 3 countries Seagen Inc.

Showing 1–14 of 14 trials

← All drugs A–Z